Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086892 · ClinicalTrials.gov registry record · Phase 2
Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00086892: Completed Phase 2 study, sponsored by Gynecologic Oncology Group.
NCT00086892 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086892, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die. Combining cetuximab with carboplatin may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab together with carboplatin works in treating patients with recurrent ovarian epithelial cancer or primary peritoneal cancer.
Interventions
- DRUG carboplatin
- BIOLOGICAL cetuximab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-06 |
| Phase | Phase 2 |
What the finished NCT00086892 record still lists
NCT00086892 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which carboplatin is the first listed.
NCT00086892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00086892 about?
NCT00086892 is a clinical study titled "Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer". RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy such as carboplatin work in different ways to stop tumor cells from dividing so they stop growing or die...
What is the current status of trial NCT00086892?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-06.
What interventions are being tested in trial NCT00086892?
The interventions under investigation include: carboplatin (DRUG), cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00086892?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia